Compare DLPN & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DLPN | CTXR |
|---|---|---|
| Founded | 1996 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.6M | 16.8M |
| IPO Year | 2008 | 2010 |
| Metric | DLPN | CTXR |
|---|---|---|
| Price | $1.60 | $0.82 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 31.2K | ★ 609.8K |
| Earning Date | 01-01-0001 | 06-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 27.81 | ★ 43.38 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $51,684,984.00 | N/A |
| Revenue This Year | $10.62 | N/A |
| Revenue Next Year | $13.78 | $147.57 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 19.85 | N/A |
| 52 Week Low | $0.75 | $0.63 |
| 52 Week High | $1.88 | $2.38 |
| Indicator | DLPN | CTXR |
|---|---|---|
| Relative Strength Index (RSI) | 54.16 | 49.42 |
| Support Level | $1.51 | $0.70 |
| Resistance Level | $1.71 | $0.98 |
| Average True Range (ATR) | 0.06 | 0.10 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 57.89 | 42.64 |
Dolphin Entertainment Inc is an independent entertainment marketing and production company. It provides strategic marketing and publicity services to many of the top brands, both individual and corporate, in the motion picture, television, music, gaming, culinary, hospitality, and lifestyle industries. It operates in two reportable segments: Entertainment publicity and marketing and Content production. It generates the majority of its revenue from the Entertainment publicity and marketing segment which provides clients with diversified marketing services, including public relations, entertainment and hospitality content marketing, strategic marketing consulting, and content production of marketing materials.
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.